EcoDrugPlus

Dna Topoisomerase 1-Like

Ensembl ID : ENSHBUG00000013826
Gene Symbol: LOC102313308
3 Cross references
207 Possible Orthologues:

Dna Topoisomerase 2-Alpha-Like

Ensembl ID : ENSHBUG00000004194
Gene Symbol: LOC102292923
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSHBUG00000005619
Gene Symbol: TOP1
3 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSHBUG00000017801
Gene Symbol: TOP2B
3 Cross references
207 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSHBUG00000012426
Gene Symbol: EML4
3 Cross references
207 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSHBUG00000014125
Gene Symbol: EPHA3
3 Cross references
210 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSHBUG00000017890
Gene Symbol: FAU
3 Cross references
300 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSHBUG00000021963
Gene Symbol: FYN
4 Cross references
196 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSHBUG00000014467
Gene Symbol: GPR119
4 Cross references
174 Possible Orthologues:

G-Protein Coupled Receptor 84-Like

Ensembl ID : ENSHBUG00000019970
Gene Symbol: LOC102313780
3 Cross references
113 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSHBUG00000014137
Gene Symbol: HCK
3 Cross references
202 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSHBUG00000000073
Gene Symbol: ITK
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).